Mechanisms involved in the development of chemotherapy-induced neuropathy

Papers of special note have been highlighted as: • of interest

References

• 1 Boyette-Davis JA, Cata JP, Zhang H et al. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J. Pain 12(9), 1017–1024 (2011).
  MedlineGoogle Scholar
• 2 Bhatnagar B, Gilmore S, Goloubeva O et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings. a single-center experience. Springerplus 3, 366 (2014).
  MedlineGoogle Scholar
• 3 Cavaletti G, Bogliun G, Marzorati L et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75, 1141–1150 (1995).
  Medline CASGoogle Scholar
• 4 Kroigard T, Schroder HD, Qvortrup C et al. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur. J. Neurol. 21(4), 623–629 (2014).
  Medline CASGoogle Scholar
• 5 de Carvalho Barbosa M, Kosturakis AK, Eng C et al. Quantitative sensory analysis of peripheral neuropathy produced by colorectal cancer and its exacerbation by cumulative dose of oxaliplatin chemotherapy. Cancer Res. 74(21), 5955–5962 (2014).
  Medline CASGoogle Scholar
• 6 Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ. Long term effects of vincristine on the peripheral nervous system. J. Neuroonocol. 15, 23–27 (1993).
  Medline CASGoogle Scholar
• 7 Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J. Pain Symptom Manage. 33(2), 166–179 (2007).
  Medline CASGoogle Scholar
• 8 Dougherty PM, Cata JP, Cordella JV, Burton A, Weng H-R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109, 132–142 (2004).
  Medline CASGoogle Scholar
• 9 Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 14(Suppl. 4), iv45–iv54 (2012).
  Medline CASGoogle Scholar
• 10 Boyette-Davis JA, Cata JP, Driver LC et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother. Pharmacol. 71, 619–626 (2013).
  Medline CASGoogle Scholar
• 11 Mols F, Beijers T, Vreugdenhil G, Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support. Care Cancer 22(8), 2261–2269 (2014).
  MedlineGoogle Scholar
• 12 Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 12(12), 1151–1161 (2011).
  Medline CASGoogle Scholar
• 13 Stoehlmacher J, Park DJ, Zhang W et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl Cancer Inst. 94(12), 936–942 (2002).
  Medline CASGoogle Scholar
• 14 Chen YC, Tzeng CH, Chen PM et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 101(2), 530–535 (2010).
  Medline CASGoogle Scholar
• 15 Kanai M, Yoshioka A, Tanaka S et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol. 34(2), 189–193 (2010).
  Medline CASGoogle Scholar
• 16 Won HH, Lee J, Park JO et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118(11), 2828–2836 (2012).• Reported on single nucleotide polymorphisms that have significant predictive validity for chemotherapy-induced peripheral neuropathy (CIPN) development.
  Medline CASGoogle Scholar
• 17 Beutler AS, Kulkarni AA, Kanwar R et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann. Neurol. 76(5), 727–737 (2014).
  Medline CASGoogle Scholar
• 18 Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 85(5), 2293–2297 (2001).
  Medline CASGoogle Scholar
• 19 Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005).
  Medline CASGoogle Scholar
• 20 Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J. Clin. Oncol. 27(8), 1243–1249 (2009).
  Medline CASGoogle Scholar
• 21 Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132(Pt 10), 2712–2723 (2009).
  MedlineGoogle Scholar
• 22 Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin. Colorectal Cancer (5 Suppl. 1), S38–S46 (2005).
  MedlineGoogle Scholar
• 23 Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29(3), 387–392 (2004).
  Medline CASGoogle Scholar
• 24 Thibault K, Calvino B, Dubacq S et al. Cortical effect of oxaliplatin associated with sustained neuropathic pain: exacerbation of cortical activity and down-regulation of potassium channel expression in somatosensory cortex. Pain 153(8), 1636–1647 (2012).
  Medline CASGoogle Scholar
• 25 Descoeur J, Pereira V, Pizzoccaro A et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 3(5), 266–278 (2011).
  Medline CASGoogle Scholar
• 26 Zhang H, Dougherty PM. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology 120(6), 1463–1475 (2014).
  Medline CASGoogle Scholar
• 27 Emery EC, Young GT, Berrocoso EM, Chen L, McNaughton PA. HCN2 ion channels play a central role in inflammatory and neuropathic pain. Science 333(6048), 1462–1466 (2011).
  Medline CASGoogle Scholar
• 28 Dimitrov AG, Dimitrova NA. A possible link of oxaliplatin-induced neuropathy with potassium channel deficit. Muscle Nerve 45(3), 403–411 (2012).
  Medline CASGoogle Scholar
• 29 Nodera H, Spieker A, Sung M, Rutkove S. Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy. Neurosci. Lett. 505(3), 223–227 (2011).
  Medline CASGoogle Scholar
• 30 Matsumoto M, Inoue M, Hald A, Xie W, Ueda H. Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J. Pharmacol. Exp. Ther. 318(2), 735–740 (2006).
  Medline CASGoogle Scholar
• 31 Flatters SJL, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 109(1–2), 150–161 (2004).
  Medline CASGoogle Scholar
• 32 Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 144(2), 714–720 (2007).
  Medline CASGoogle Scholar
• 33 Thibault K, Van Steenwinckel J, Brisorgueil MJ et al. Serotonin 5-HT2A receptor involvement and Fos expression at the spinal level in vincristine-induced neuropathy in the rat. Pain 140(2), 305–322 (2008).
  Medline CASGoogle Scholar
• 34 Hansen N, Uceyler N, Palm F et al. Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. Neurosci. Lett. 495(2), 93–97 (2011).
  Medline CASGoogle Scholar
• 35 Carozzi VA, Canta A, Chiorazzi A, Cavaletti G. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci. Lett. (2014).
  MedlineGoogle Scholar
• 36 Ghelardini C, Menicacci C, Cerretani D, Bianchi E. Spinal administration of mGluR5 antagonist prevents the onset of bortezomib induced neuropathic pain in rat. Neuropharmacology 86, 294–300 (2014).
  Medline CASGoogle Scholar
• 37 Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. GLIA 53(2), 212–224 (2006).
  MedlineGoogle Scholar
• 38 Robinson CR, Dougherty PM. Spinal astrocute gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy. Neuroscience 285(1), 1–10 (2015).
  Medline CASGoogle Scholar
• 39 Cata JP, Weng HR, Chen JH, Dougherty PM. Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. Neuroscience 138(1), 329–338 (2006).
  Medline CASGoogle Scholar
• 40 Cata JP, Weng H-R, Dougherty PM. Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res. 1230, 91–98 (2008).
  Medline CASGoogle Scholar
• 41 Weng H-R, Cordella JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 103, 131–138 (2003).
  Medline CASGoogle Scholar
• 42 Yang Y, Zhang YG, Lin GA et al. Spinal changes of a newly isolated neuropeptide endomorphin-2 concomitant with vincristine-induced allodynia. PLoS ONE 9(2), e89583 (2014).
  MedlineGoogle Scholar
• 43 Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol. Res. 67(1), 94–109 (2013).
  Medline CASGoogle Scholar
• 44 Uhelski ML, Khasabova IA, Simone DA. Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. J. Neurophysiol. 113(5), 1501–1510 (2015).
  Medline CASGoogle Scholar
• 45 Janes K, Esposito E, Doyle T et al. A₃ adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. Pain 155, 2560–2567 (2015).
  Google Scholar
• 46 Nagy I, Friston D, Valente JS, Torres Perez JV, Andreou AP. Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel. Prog. Drug Res. 68, 39–76 (2014).
  Medline CASGoogle Scholar
• 47 Simone DA, Baumann TK, LaMotte RH. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain 38, 99–107 (1989).
  Medline CASGoogle Scholar
• 48 Marchettini P, Simone DA, Caputi G, Ochoa JL. Pain from excitation of identified muscle nociceptors in humans. Brain Res. 740(1–2), 109–116 (1996).
  Medline CASGoogle Scholar
• 49 Witting N, Svensson P, Gottrup H, Arendt-Nielsen L, Jensen TS. Intramuscular and intradermal injection of capsaicin: a comparison of local and referred pain. Pain 84(2–3), 407–412 (2000).
  Medline CASGoogle Scholar
• 50 Hara T, Chiba T, Abe K et al. Effect of paclitaxel on transient receptor potential vallinoid 1 in rat dorsal root ganglion. Pain 154, 882–889 (2013).
  Medline CASGoogle Scholar
• 51 Quartu M, Carozzi VA, Dorsey SG et al. Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve. Biomed. Res. Int. 2014, 180428 (2014).
  Medline CASGoogle Scholar
• 52 Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol. Pain 6, 15– (2010).
  MedlineGoogle Scholar
• 53 Laursen WJ, Bagriantsev SN, Gracheva EO. TRPA1 channels: chemical and temperature sensitivity. Curr. Top. Membr. 74, 89–112 (2014).
  Medline CASGoogle Scholar
• 54 Wei H, Koivisto A, Saarnilehto M et al. Spinal transient receptor potential ankyrin 1 channel contributes to central pain hypersensitivity in various pathophysiological conditions in the rat. Pain 152(3), 582–591 (2011).
  Medline CASGoogle Scholar
• 55 Nassini R, Gees M, Harrison S et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 152(7), 1621–1631 (2011).
  Medline CASGoogle Scholar
• 56 Zhao M, Isami K, Nakamura S, Shirakawa H, Nakagawa T, Kaneko S. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol. Pain 8, 55 (2012).
  Medline CASGoogle Scholar
• 57 Materazzi S, Fusi C, Benemei S et al. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pflugers Arch. 463, 561–569 (2012).
  Medline CASGoogle Scholar
• 58 Chen J, Kang D, Xu J et al. Species differences and molecular determinant of TRPA1 cold sensitivity. Nat. Commun. 4, 2501 (2013).• Species differences and molecular determinant of TRPA1 cold sensitivity.
  MedlineGoogle Scholar
• 59 Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 193, 440–451 (2011).
  Medline CASGoogle Scholar
• 60 Peier AM, Reeve AJ, Andersson DA et al. A heat-sensitive TRP channel expressed in keratinocytes. Science 296, 2046–2049 (2002).
  Medline CASGoogle Scholar
• 61 Proudfoot CJ, Garry EM, Cottrell DF et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr. Biol. 16(16), 1591–1605 (2006).
  Medline CASGoogle Scholar
• 62 Storey DJ, Colvin LA, Mackean MJ, Mitchell R, Fleetwood-Walker SM, Fallon MT. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRM8 activator menthol, enables further effective chemotherapy delivery. J. Pain Symptom. Manag. 39(6), e2–e4 (2010).
  MedlineGoogle Scholar
• 63 Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol induces caspase-10-dependent apoptosis. J. Biol. Chem. 279(49), 51057–51067 (2004).
  Medline CASGoogle Scholar
• 64 Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J. Pain 10(5), 534–541 (2009).
  Medline CASGoogle Scholar
• 65 Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur. J. Neurosci. 20(11), 2896–2902 (2004).
  MedlineGoogle Scholar
• 66 Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27(6), 992–1002 (2006).
  Medline CASGoogle Scholar
• 67 Scuteri A, Galimberti A, Maggioni D et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 30(2), 312–319 (2009).
  Medline CASGoogle Scholar
• 68 Scuteri A, Galimberti A, Ravasi M et al. NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neurosci. Lett. 486(3), 141–145 (2010).
  Medline CASGoogle Scholar
• 69 Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122(3), 245–257 (2006).
  Medline CASGoogle Scholar
• 70 Xiao WH, Zheng H, Zheng FY, Nuydens R, Meert TF, Bennett GJ. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 199, 461–469 (2011).
  Medline CASGoogle Scholar
• 71 Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp. Neurol. 232(2), 154–161 (2011).
  Medline CASGoogle Scholar
• 72 Xiao WH, Bennett GJ. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents paclitaxel and oxaliplatin. Pain 153, 704–709 (2012).
  Medline CASGoogle Scholar
• 73 Zheng H, Xiao WH, Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp. Neurol. 238(2), 225–234 (2012).
  Medline CASGoogle Scholar
• 74 Flatters SJ, Xiao WH, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci. Lett. 397(3), 219–223 (2006).• Indicated ALCAR as a potential prevention of CIPN.
  Medline CASGoogle Scholar
• 75 Pisano C, Pratesi G, Laccabue D et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin. Cancer Res. 9(15), 5756–5767 (2003).
  Medline CASGoogle Scholar
• 76 Ghirardi O, Lo GP, Pisano C et al. Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res. 25(4), 2681–2687 (2005).
  Medline CASGoogle Scholar
• 77 Jin HW, Flatters SJ, Xiao WH, Mulhern HL, Bennett GJ. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp. Neurol. 210(1), 229–237 (2008).
  Medline CASGoogle Scholar
• 78 Bianchi G, Vitali G, Caraceni A et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur. J. Cancer 41(12), 1746–1750 (2005).
  Medline CASGoogle Scholar
• 79 Maestri A, De Pasquale CA, Cundari S, Zanna C, Cortesi E, Crino L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 91(2), 135–138 (2005).
  Medline CASGoogle Scholar
• 80 Callander N, Markovina S, Eickhoff J et al. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother. Pharmacol. 74(4), 875–882 (2014).• Clinical trial that did not find significant prevention of CIPN with ALCAR.
  Medline CASGoogle Scholar
• 81 Hershman DL, Unger JM, Crew KD et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J. Clin. Oncol. 31(20), 2627–2633 (2013).
  Medline CASGoogle Scholar
• 82 Hui KF, Lam BH, Ho DN, Tsao SW, Chiang AK. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol. Cancer Ther. 12(5), 747–758 (2013).
  Medline CASGoogle Scholar
• 83 Barriere DA, Rieusset J, Chanteranne D et al. Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and TRPA1 sensitization. Pain 153(3), 553–561 (2012).
  Medline CASGoogle Scholar
• 84 Kim HK, Zhang YP, Gwak YS, Abdi S. Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology 112(2), 432–439 (2010).
  Medline CASGoogle Scholar
• 85 Fidanboylu M, Griffiths LA, Flatters SJ. Global inhibition of reactive oxygen species (ROS) inhibits paclitaxel-induced painful peripheral neuropathy. PLoS ONE 6(9), e25212 (2011).
  Medline CASGoogle Scholar
• 86 Doyle T, Chen Z, Muscoli C et al. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J. Neurosci. 32(18), 6149–6160 (2012).
  Medline CASGoogle Scholar
• 87 Areti A, Yerra VG, Naidu V, Kumar A. Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox. Biol. 2, 289–295 (2014).
  Medline CASGoogle Scholar
• 88 Kelley MR, Jiang Y, Guo C, Reed A, Meng H, Vasko MR. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS ONE 9(9), e106485 (2014).
  MedlineGoogle Scholar
• 89 Santin G, Scietti L, Veneroni P, Barni S, Bernocchi G, Bottone MG. Effects of Cisplatin in neuroblastoma rat cells: damage to cellular organelles. Int. J. Cell Biol. 2012, 424072 (2012).
  MedlineGoogle Scholar
• 90 Santin G, Piccolini VM, Veneroni P, Barni S, Bernocchi G, Bottone MG. Different patterns of apoptosis in response to cisplatin in B50 neuroblastoma rat cells. Histol. Histopathol. 26(7), 831–842 (2011).
  Medline CASGoogle Scholar
• 91 Shin YK, Jang SY, Lee HK et al. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy. GLIA 58(16), 1961–1976 (2010).
  MedlineGoogle Scholar
• 92 Argyriou AA, Polychronopoulos P, Iconomou G et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol. 46(8), 1131–1137 (2007).
  Medline CASGoogle Scholar
• 93 Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin. Breast Cancer 11(2), 73–81 (2011).
  Medline CASGoogle Scholar
• 94 Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 24(10), 1633–1642 (2006).
  Medline CASGoogle Scholar
• 95 LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 37, 231–239 (2013).
  Medline CASGoogle Scholar
• 96 Staff NP, Podratz JL, Grassner L et al. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 39, 124–131 (2013).
  Medline CASGoogle Scholar
• 97 Schellingerhout D, LeRoux LG, Hobbs BP, Bredow S. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS ONE 7(9), e45776 (2012).
  Medline CASGoogle Scholar
• 98 Boyette-Davis J, Xin W, Zhang H, Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 152(2), 308–313 (2011).
  Medline CASGoogle Scholar
• 99 Boyette-Davis J, Dougherty PM. Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp. Neurol. 229(2), 353–357 (2011).
  Medline CASGoogle Scholar
• 100 Lehmann HC, Chen W, Borzan J, Mankowski JL, Hoke A. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Ann. Neurol. 69(1), 100–110 (2011).
  Medline CASGoogle Scholar
• 101 Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain 92(1–2), 139–145 (2001).
  Medline CASGoogle Scholar
• 102 Zhang H, Boyette-Davis JA, Kosturakis AK et al. Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. J. Pain 14(10), 1031–1044 (2013).
  Medline CASGoogle Scholar
• 103 Cata JP, Weng H-R, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anes. 72, 151–169 (2006).
  Medline CASGoogle Scholar
• 104 Cavaletti G, Cavaletti E, Oggioni N et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 21(3), 389–394 (2000).
  Medline CASGoogle Scholar
• 105 Ozturk G, Erdogan E, Anlar O, Kosem M, TaspInar M. Effect of leukemia inhibitory factor in experimental cisplatin neuropathy in mice. Cytokine 29(1), 31–41 (2005).
  Medline CASGoogle Scholar
• 106 Cliffer KD, Siuciak JA, Carson SR et al. Physiological characterization of taxol-induced large fiber sensory neuropathy in the rat. Ann. Neurol. 43, 46–55 (1998).
  Medline CASGoogle Scholar
• 107 Takeda M, Tanimoto T, Kadoi J et al. Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation. Pain 129(1–2), 155–166 (2007).
  Medline CASGoogle Scholar
• 108 Warwick RA, Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur. J. Pain 17, 571–580 (2013).
  Medline CASGoogle Scholar
• 109 Zhang H, Yoon S-Y, Zhang H, Dougherty PM. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of paclitaxel-induced painful neuropathy. J. Pain 13(3), 293–303 (2012).
  Medline CASGoogle Scholar
• 110 Robinson CR, Zhang H, Dougherty PM. Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy. Neuroscience 274(1), 308–317 (2014).• Bortezomib results in mechanical hyperalgesia via decreased glutamate transporter expression and increased astrocytic gap junction coupling.
  Medline CASGoogle Scholar
• 111 Gao YJ, Zhang L, Samad OA et al. JNK-Induced MCP-1 Production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J. Neurosci. 29(13), 4096–4108 (2009).
  Medline CASGoogle Scholar
• 112 Yoon S-Y, Robinson CR, Zhang H, Dougherty PM. Gap junction protein connexin 43 is involved in the induction of oxaliplatin-related neuropathic pain. J. Pain 14(2), 205–214 (2013).
  Medline CASGoogle Scholar
• 113 Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumor necrosis factor a. Br. J. Pharmacol. 121, 417–424 (1997).
  Medline CASGoogle Scholar
• 114 Binshtok AM, Wang H, Zimmermann K et al. Nociceptors Are Interleukin-1 beta Sensors. J. Neurosci. 28(52), 14062–14073 (2008).
  Medline CASGoogle Scholar
• 115 Cunha JM, Cunha FQ, Poole S, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br. J. Pharmacol. 130(6), 1418–1424 (2000).
  Medline CASGoogle Scholar
• 116 Sorkin LS, Xaio W-H, Wagner R, Myers RR. Tumour necrosis factor-a induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81(1), 255–262 (1997).
  Medline CASGoogle Scholar
• 117 Ozaktay AC, Cavanaugh JM, Asik I, DeLeo JA, Weinstein JN. Dorsal root sensitivity to interleukin-1 beta, interleukin-6 and tumor necrosis factor in rats. Eur. Spine J. 11, 467–475 (2002).
  MedlineGoogle Scholar
• 118 Onda A, Hamba M, Yabuki S, Kikuchi S. Exogenous tumor necrosis factor-alpha induces abnormal discharges in rat dorsal horn neurons. Spine (Phila Pa 1976.) 27(15), 1618–1624 (2002).
  Google Scholar
• 119 Zhang H, Nei H, Dougherty PM. A p38 mitogen-activated protein kinase-dependent mechanism of disinhibition in spinal synaptic transmission induced by tumor necrosis factor-alpha. J. Neurosci. 30(38), 12844–12855 (2010).
  Medline CASGoogle Scholar
• 120 McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp. Neurol. 192(2), 444–462 (2005).
  Medline CASGoogle Scholar
• 121 Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic b-cell to treat diabetes. Nat. Rev. Drug Discov. 13(4), 278–289 (2014).
  Medline CASGoogle Scholar
• 122 Zaks-Zilberman M, Zaks TZ, Vogel SN. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 15(3), 156–165 (2001).
  Medline CASGoogle Scholar
• 123 Basu S, Sodhi A. Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol. Cell Biol. 70(Pt 1), 15–24 (1992).
  Medline CASGoogle Scholar
• 124 Weintraub M, Adde MA, Venzon DJ et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J. Clin. Oncol. 14(3), 935–940 (1996).
  Medline CASGoogle Scholar
• 125 Ledeboer A, Jekich BM, Sloane EM et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun. 21, 686–698 (2007).
  Medline CASGoogle Scholar
• 126 Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of taxol. Eur. J. Immunol. 31, 2448–2457 (2001).
  Medline CASGoogle Scholar
• 127 Li Y, Zhang H, Zhang H, Kosturakis AK, Jawad AB, Dougherty PM. Toll-like receptor 4 signaling in primary sensory neurons and spinal astrocytes contribute to paclitaxel-induced peripheral neuropathy. J. Pain 15(7), 712–725 (2014).
  Medline CASGoogle Scholar
• 128 Park HJ, Stokes JA, Corr M, Yaksh TL. Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice. Cancer Chemother. Pharmacol. 73(1), 25–34 (2014).
  Medline CASGoogle Scholar
• 129 Zhang ZJ, Dong YL, Lu Y, Cao S, Zhao ZQ, Gao YJ. Chemokine CCL2 and its receptor CCR2 in the medullary dorsal horn are involved in trigeminal neuropathic pain. J. Neuroinflammation 9, 136– (2012).
  Medline CASGoogle Scholar
• 130 Abbadie C, Lindia JA, Cumiskey AM et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc. Natl Acad. Sci. USA 100(13), 7947–7952 (2003).
  Medline CASGoogle Scholar
• 131 Hershman DL, Lacchetti C, Loprinzi CL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary. J. Oncol. Pract. 10(6), e421–e424 (2014).• Recent review article summarizing the agents that have failed to demonstrate effective prevention of CIPN.
  MedlineGoogle Scholar
• 132 Anand P, Shenoy R, Palmer JE et al. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur. J. Pain 15(10), 1040–1048 (2011).
  Medline CASGoogle Scholar
• 133 Ostenfeld T, Krishen A, Lai RY et al. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study. Eur. J. Pain 17(6), 844–857 (2013).
  Medline CASGoogle Scholar